Hester Biosciences
1,445.60
-6.60(-0.45%)
Market Cap₹1,229.75 Cr
PE Ratio29.27
IndustryHealthcare
Company Performance:
1D-0.45%
1M-4.77%
6M-31.74%
1Y+5.57%
5Y-13.34%
View Company Insightsright
More news about Hester Biosciences
12Nov 25
Hester Biosciences Reports Mixed Q2 Results: Consolidated Profit Surges 71% Despite Revenue Decline
Hester Biosciences Limited announced its Q2 FY26 results, showing a 15% decline in consolidated revenue to INR 709.69 million, but a 71% increase in profit after tax to INR 143.31 million. The Poultry Healthcare Division grew by 18%, while the Animal Healthcare Division saw a 50% decline due to delays in government immunization programs. The company received market authorization for the H9N2 vaccine and implemented cost optimization measures. Hester Africa reported a net profit of INR 48.20 million, while Hester Nepal faced challenges. The company maintains strong market positions in various segments and expects to regain momentum in Animal Healthcare as government programs resume.
 no imag found
04Aug 25
Hester Biosciences Reports Mixed Q1 Results with Strong Africa Turnaround Despite India Business Headwinds
Hester Biosciences reported mixed Q1 results. Standalone revenue declined 14% to INR 63.00 crores, with PAT down 7%, due to delayed government immunization programs. Animal Health division saw a 33% decline, while Poultry Healthcare grew 2%. Consolidated PAT grew over 100%, driven by international performance. Hester Africa achieved a significant turnaround, posting INR 5.00 crores profit on INR 17.00 crores revenue. Management remains optimistic about future growth, expecting institutional demand to normalize and awaiting regulatory clearances for new vaccine launches.
 no imag found
01Aug 25
Hester Biosciences Reports Mixed Q1 Results: Consolidated Profit Surges 131% Despite Standalone Decline
Hester Biosciences Limited reported mixed Q1 results. Consolidated revenue increased 2% to ₹841.05 crore, with net profit surging 131% to ₹172.96 crore. EBITDA margin improved to 31%. Standalone revenue decreased 14% to ₹634.90 crore, with net profit declining 7% to ₹78.38 crore. Animal Healthcare Division faced challenges with a 33% sales decline, while Poultry Healthcare Division grew 2%. Subsidiaries performed well, with Hester Africa showing a significant turnaround. The company remains focused on product diversification and leveraging international infrastructure for future growth.
 no imag found
09May 25
Hester Biosciences Declares Dividend Amidst Q4 Profit Decline
Hester Biosciences announced a ₹7 per share dividend despite a 73.74% drop in Q4 consolidated net profit to ₹13 million. Revenue increased by 4.05% to ₹72 crore, while sales decreased by 5.67%. EBITDA rose 11.29%, but operating profit halved. The company reported a significant increase in other income to ₹8.80 crore, potentially offsetting operational challenges.
 no imag found
Hester Biosciences
1,445.60
-6.60
(-0.45%)
1 Year Returns:+5.57%
Industry Peers
Sun Pharmaceutical
1,812.80
(+0.30%)
Divis Laboratories
6,372.00
(+0.66%)
Torrent Pharmaceuticals
4,427.80
(+1.24%)
Dr Reddys Laboratories
1,314.60
(+2.14%)
Cipla
1,333.50
(+0.64%)
Lupin
2,337.40
(+1.49%)
Zydus Life Science
923.10
(+1.57%)
Mankind Pharma
2,237.70
(+3.44%)
Aurobindo Pharma
1,285.90
(+3.09%)
Alkem Laboratories
5,616.50
(+2.87%)